The impact of continuous renal replacement therapy on drug therapy

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 562-565

  Susla, G M ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTICOAGULATION; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DISEASE EXACERBATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; HEMODIALYSIS; HUMAN; HYPERVOLEMIA; INFECTION; KIDNEY BLOOD FLOW; MOLECULAR WEIGHT; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SHORT SURVEY; SOLUTE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMICS; HEMOFILTRATION; HUMANS; MULTIPLE ORGAN FAILURE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL REPLACEMENT THERAPY;

EID: 70350247734     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.152     Document Type: Short Survey

References (29)

1. Kramer, P., Wigger, W., Rieger, J., Matthaei, D. & Scheler, F. Arteriovenous haemofltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin. Wochenschr. 55, 1121-1122 (1977).
2. Forni, L.G. & Hilton, P.J. Continuous hemofltration in the treatment of acute renal failure. N. Engl. J. Med. 336, 1303-1309 (1997).
3. Foote, C.L. & Fraser, J.F. So you need to start renal replacement therapy on your ICU patient? Curr. Anaesth. Crit. Care 16, 321-329 (2005).
4. Reetze-Bonorden, P., Bohler, J. & Keller, E. Drug dosage in patients during continuous renal replacement therapy pharmacokinetic and therapeutic considerations. Clin. Pharmacokinet. 24, 362-379 (1991).
5. Schetz, M., Ferdinande, P., Van den Berghe, G., Verwaest, C. & Lauwers, P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care. Med. 21, 612-620 (1995).
6. Fuhrmann, V., Schenk, P., Jaeger, W., Ahmed, S. & Thalhammer, F. Pharmacokinetics of moxifoxacin in patients undergoing continuous venovenous haemodiafltration. J. Antimicrob. Chemother. 54, 780-784 (2004).
7. Mueller, B.A., Scarim, S.K. & Macias, W.L. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofltration. Am. J. Kidney Dis. 21, 172-179 (1993).
8. Nolin, T.D., Naud, J., Leblond, F.A. & Pichette, V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83, 898-903 (2008).
9. Green, L., Dick, J.D., Goldberger, S.P. & Angelopulos, C.M. Prolonged elimination of piperacillin in a patient with renal and liver failure. Drug Intell. Clin. Pharm. 19, 427-429 (1985).
10. Golper, T.A. & Marx, M.A. Drug dosing adjustments during continuous renal replacement therapies. Kidney Int. Suppl. 66, S165-S168 (1998).
11. Lee, C.S. & Marbury, T.C. Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 9, 42-66 (1984).
12. Swart, E.L., de Jongh, J., Zuideveld, K.P., Danhof, M., Thijs, L.G. & Strack van Schijndel, R.J. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofltration. Am. J. Kidney Dis. 45, 360-371 (2005).
13. Golper, T.A., Wedel, S.K., Kaplan, A.A., Saad, A.M., Donta, S.T. & Paganini, E.P. Drug removal during continuous arteriovenous hemofltration: theory and clinical observations. Int. J. Artif. Organs. 8, 307-312 (1985).
14. Thalhammer, F. et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofltration. Antimicrob. Agents Chemother. 42, 2417-2420 (1998).
15. Tegeder, I., Neumann, F., Bremer, F., Brune, K., Lötsch, J. & Geisslinger, G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofltration. Clin. Pharmacol. Ther. 65, 50-57 (1999).
16. Valtonen, M., Tiula, E., Backman, J.T. & Neuvonen, P.J. Elimination of meropenem during continuous veno-venous haemofltration and haemodiafltration in patients with acute renal failure. J. Antimicrob. Chemother. 45, 701-704 (2000).
17. Aucella, F., Di Paolo, S. & Gesualdo, L. Dialysate and replacement fuid composition for CRRT. Contrib. Nephrol. 156, 287-296 (2007).
18. Bellomo, R. & Ronco, C. Acute renal replacement therapy: haemofltration or haemodiafltration or haemodialysis. Int. J. Intensive Care Med. 12, 30-37, (2005).
19. Arzuaga, A. et al. Infuence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofltration. J. Clin. Pharmacol. 45, 168-176 (2005).
20. Bohler, J., Donauer, J. & Keller, F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int. 56 (Suppl 72)S24-S28 (1999).
21. Bickley, S.K. Drug dosing during continuous arteriovenous hemofltration. Clin. Pharm. 7, 198-206 (1988).
22. Mueller, B.A., Pasko, D.A. & Sowinski, K.M. Higher renal replacement therapy dose delivery infuences on drug therapy. Artif. Organs. 27, 808-814 (2003).
23. Krueger, W.A. et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafltration. Antimicrob. Agents Chemother. 42, 2421-2424 (1998).
24. Langgartner, J., Vasold, A., Glück, T., Reng, M. & Kees, F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care. Med. 34, 1091-1096 (2008).
25. Zarowitz, B.J., Anandan, J.V., Dumler, F., Jayashankar, J. & Levin, N. Continuous arteriovenous hemofltration of aminoglycoside antibiotics in critically ill patients. J. Clin. Pharmacol. 26, 686-689 (1986).
26. Golper, T.A., Pulliam, J. & Bennett, W.M. Removal of therapeutic drugs by continuous arteriovenous hemofltration. Arch. Intern. Med. 145, 1651-1652 (1985).
27. Keller, E., Fecht, J., Bohler, J. & Schollmeyer, P. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous hemofltration in intensive care patients. Nephrol. Dial. Transplant. 4, 64-645 (1989).
28. Trotman, R.L., Williamson, J.C., Shoemaker, D.M. & Salzer, W.L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41, 1159-1166 (2005).
29. Krueger, W.A. et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofltration. Chemotherapy 49, 280-286 (2003).